The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform
M J Tikkanen - One of the best experts on this subject based on the ideXlab platform.
-
Lynestrenol induced therapeutic amenorrhea effects of dose reduction on serum sex hormones and lipids
Acta Obstetricia et Gynecologica Scandinavica, 1992Co-Authors: Kari J L Huovinen, Pekka Lahteenmaki, Joma Karkkainen, M J TikkanenAbstract:The effect of reducing the dose of peroral Lynestrenol by half on serum sex-hormone, lipid and lipoprotein status was studied in 21 mentally retarded women with therapeutic amenorrhea (TA). They had previously received 5 or 10 mg peroral Lynestrenol daily for periods ranging from 32 to 196 months. Dose halving of Lynestrenol resulted in an increase in serum total testosterone (T) by 16% (p less than 0.05), sex-hormone binding globulin (SHBG) by 39% (p less than 0.01) and high-density lipoprotein cholesterol (HDL-C) by 28% (p less than 0.001). Both the mean serum total and free concentrations of norethisterone (NET and fNET) decreased by 60% (p less than 0.001). The serum concentrations of 17-beta-estradiol (E2), its free fractions (fE2) and free T (fT) were not significantly altered. Significant correlations were observed between the change in HDL-C and the change in T (r = 0.45, p less than 0.05), between the change in SHBG and the change in T (r = 0.62, p less than 0.01), fT (r = 0.43, p less than 0.05) and E2 (r = 0.51, p less than 0.05). The elevation of HDL-C was probably caused by the reduced serum NET concentrations. This also resulted in an increase in serum SHBG concentration, which is regarded as an indicator of the overall estrogen/androgen ratio.
-
serum lipids and lipoproteins during therapeutic amenorrhea induced by Lynestrenol and depot medroxyprogesterone acetate
Acta Obstetricia et Gynecologica Scandinavica, 1991Co-Authors: K Huovinen, M J Tikkanen, S Autio, T Harkonen, L Lommi, S Varonen, M L WilskaAbstract:Serum concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), apolipoprotein A1 (Apo A1), and apolipoprotein B (Apo B) were determined in mentally handicapped subjects (n = 87). 33 women were on Lynestrenol 5–10 mg for therapeutic amenorrhea (TA). 18 of them were randomly allocated to continue on Lynestrenol and 15 were switched to intramuscular administration of medrozyprogesterone (DMPA). The switch to DMPA resulted in significant increases in HDL-C (33%), Apo A1 (12%), as well as in the HDL-C/LDL-C (48%) and Apo Ai/Apo B (22%) ratios. The concentrations of HDL-C and Apo A1 were significantly greater in patients receiving DMPA, than in patients continuing with Lynestrenol therapy. The amenorrhea incidence, however, did not differ between the two therapy groups. It is concluded that therapy with DMPA may be associated with smaller atherosclerosis risk than with peroral Lynestrenol, because of its weaker effect on H...
Kari J L Huovinen - One of the best experts on this subject based on the ideXlab platform.
-
Lynestrenol induced therapeutic amenorrhea effects of dose reduction on serum sex hormones and lipids
Acta Obstetricia et Gynecologica Scandinavica, 1992Co-Authors: Kari J L Huovinen, Pekka Lahteenmaki, Joma Karkkainen, M J TikkanenAbstract:The effect of reducing the dose of peroral Lynestrenol by half on serum sex-hormone, lipid and lipoprotein status was studied in 21 mentally retarded women with therapeutic amenorrhea (TA). They had previously received 5 or 10 mg peroral Lynestrenol daily for periods ranging from 32 to 196 months. Dose halving of Lynestrenol resulted in an increase in serum total testosterone (T) by 16% (p less than 0.05), sex-hormone binding globulin (SHBG) by 39% (p less than 0.01) and high-density lipoprotein cholesterol (HDL-C) by 28% (p less than 0.001). Both the mean serum total and free concentrations of norethisterone (NET and fNET) decreased by 60% (p less than 0.001). The serum concentrations of 17-beta-estradiol (E2), its free fractions (fE2) and free T (fT) were not significantly altered. Significant correlations were observed between the change in HDL-C and the change in T (r = 0.45, p less than 0.05), between the change in SHBG and the change in T (r = 0.62, p less than 0.01), fT (r = 0.43, p less than 0.05) and E2 (r = 0.51, p less than 0.05). The elevation of HDL-C was probably caused by the reduced serum NET concentrations. This also resulted in an increase in serum SHBG concentration, which is regarded as an indicator of the overall estrogen/androgen ratio.
Pekka Lahteenmaki - One of the best experts on this subject based on the ideXlab platform.
-
Lynestrenol induced therapeutic amenorrhea effects of dose reduction on serum sex hormones and lipids
Acta Obstetricia et Gynecologica Scandinavica, 1992Co-Authors: Kari J L Huovinen, Pekka Lahteenmaki, Joma Karkkainen, M J TikkanenAbstract:The effect of reducing the dose of peroral Lynestrenol by half on serum sex-hormone, lipid and lipoprotein status was studied in 21 mentally retarded women with therapeutic amenorrhea (TA). They had previously received 5 or 10 mg peroral Lynestrenol daily for periods ranging from 32 to 196 months. Dose halving of Lynestrenol resulted in an increase in serum total testosterone (T) by 16% (p less than 0.05), sex-hormone binding globulin (SHBG) by 39% (p less than 0.01) and high-density lipoprotein cholesterol (HDL-C) by 28% (p less than 0.001). Both the mean serum total and free concentrations of norethisterone (NET and fNET) decreased by 60% (p less than 0.001). The serum concentrations of 17-beta-estradiol (E2), its free fractions (fE2) and free T (fT) were not significantly altered. Significant correlations were observed between the change in HDL-C and the change in T (r = 0.45, p less than 0.05), between the change in SHBG and the change in T (r = 0.62, p less than 0.01), fT (r = 0.43, p less than 0.05) and E2 (r = 0.51, p less than 0.05). The elevation of HDL-C was probably caused by the reduced serum NET concentrations. This also resulted in an increase in serum SHBG concentration, which is regarded as an indicator of the overall estrogen/androgen ratio.
Joma Karkkainen - One of the best experts on this subject based on the ideXlab platform.
-
Lynestrenol induced therapeutic amenorrhea effects of dose reduction on serum sex hormones and lipids
Acta Obstetricia et Gynecologica Scandinavica, 1992Co-Authors: Kari J L Huovinen, Pekka Lahteenmaki, Joma Karkkainen, M J TikkanenAbstract:The effect of reducing the dose of peroral Lynestrenol by half on serum sex-hormone, lipid and lipoprotein status was studied in 21 mentally retarded women with therapeutic amenorrhea (TA). They had previously received 5 or 10 mg peroral Lynestrenol daily for periods ranging from 32 to 196 months. Dose halving of Lynestrenol resulted in an increase in serum total testosterone (T) by 16% (p less than 0.05), sex-hormone binding globulin (SHBG) by 39% (p less than 0.01) and high-density lipoprotein cholesterol (HDL-C) by 28% (p less than 0.001). Both the mean serum total and free concentrations of norethisterone (NET and fNET) decreased by 60% (p less than 0.001). The serum concentrations of 17-beta-estradiol (E2), its free fractions (fE2) and free T (fT) were not significantly altered. Significant correlations were observed between the change in HDL-C and the change in T (r = 0.45, p less than 0.05), between the change in SHBG and the change in T (r = 0.62, p less than 0.01), fT (r = 0.43, p less than 0.05) and E2 (r = 0.51, p less than 0.05). The elevation of HDL-C was probably caused by the reduced serum NET concentrations. This also resulted in an increase in serum SHBG concentration, which is regarded as an indicator of the overall estrogen/androgen ratio.
M L Wilska - One of the best experts on this subject based on the ideXlab platform.
-
serum lipids and lipoproteins during therapeutic amenorrhea induced by Lynestrenol and depot medroxyprogesterone acetate
Acta Obstetricia et Gynecologica Scandinavica, 1991Co-Authors: K Huovinen, M J Tikkanen, S Autio, T Harkonen, L Lommi, S Varonen, M L WilskaAbstract:Serum concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), apolipoprotein A1 (Apo A1), and apolipoprotein B (Apo B) were determined in mentally handicapped subjects (n = 87). 33 women were on Lynestrenol 5–10 mg for therapeutic amenorrhea (TA). 18 of them were randomly allocated to continue on Lynestrenol and 15 were switched to intramuscular administration of medrozyprogesterone (DMPA). The switch to DMPA resulted in significant increases in HDL-C (33%), Apo A1 (12%), as well as in the HDL-C/LDL-C (48%) and Apo Ai/Apo B (22%) ratios. The concentrations of HDL-C and Apo A1 were significantly greater in patients receiving DMPA, than in patients continuing with Lynestrenol therapy. The amenorrhea incidence, however, did not differ between the two therapy groups. It is concluded that therapy with DMPA may be associated with smaller atherosclerosis risk than with peroral Lynestrenol, because of its weaker effect on H...
